JP2021513967A5 - - Google Patents

Info

Publication number
JP2021513967A5
JP2021513967A5 JP2020543326A JP2020543326A JP2021513967A5 JP 2021513967 A5 JP2021513967 A5 JP 2021513967A5 JP 2020543326 A JP2020543326 A JP 2020543326A JP 2020543326 A JP2020543326 A JP 2020543326A JP 2021513967 A5 JP2021513967 A5 JP 2021513967A5
Authority
JP
Japan
Prior art keywords
groups
group
independently selected
ring
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513967A (ja
JP7214743B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018042 external-priority patent/WO2019161078A1/en
Publication of JP2021513967A publication Critical patent/JP2021513967A/ja
Publication of JP2021513967A5 publication Critical patent/JP2021513967A5/ja
Priority to JP2022100979A priority Critical patent/JP2022126802A/ja
Application granted granted Critical
Publication of JP7214743B2 publication Critical patent/JP7214743B2/ja
Priority to JP2024015975A priority patent/JP2024050811A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543326A 2018-02-15 2019-02-14 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 Active JP7214743B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022100979A JP2022126802A (ja) 2018-02-15 2022-06-23 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
JP2024015975A JP2024050811A (ja) 2018-02-15 2024-02-05 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862631453P 2018-02-15 2018-02-15
US62/631,453 2018-02-15
PCT/US2019/018042 WO2019161078A1 (en) 2018-02-15 2019-02-14 Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100979A Division JP2022126802A (ja) 2018-02-15 2022-06-23 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法

Publications (3)

Publication Number Publication Date
JP2021513967A JP2021513967A (ja) 2021-06-03
JP2021513967A5 true JP2021513967A5 (cg-RX-API-DMAC7.html) 2022-02-21
JP7214743B2 JP7214743B2 (ja) 2023-01-30

Family

ID=65529899

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543326A Active JP7214743B2 (ja) 2018-02-15 2019-02-14 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
JP2022100979A Withdrawn JP2022126802A (ja) 2018-02-15 2022-06-23 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
JP2024015975A Withdrawn JP2024050811A (ja) 2018-02-15 2024-02-05 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022100979A Withdrawn JP2022126802A (ja) 2018-02-15 2022-06-23 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
JP2024015975A Withdrawn JP2024050811A (ja) 2018-02-15 2024-02-05 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法

Country Status (42)

Country Link
US (3) US11066417B2 (cg-RX-API-DMAC7.html)
EP (2) EP4198037A1 (cg-RX-API-DMAC7.html)
JP (3) JP7214743B2 (cg-RX-API-DMAC7.html)
KR (1) KR102482271B1 (cg-RX-API-DMAC7.html)
CN (2) CN117285547A (cg-RX-API-DMAC7.html)
AR (1) AR114254A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019222758B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015509A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002055A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200403A (cg-RX-API-DMAC7.html)
DK (1) DK3752510T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000016A (cg-RX-API-DMAC7.html)
EA (1) EA202091930A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20053845A (cg-RX-API-DMAC7.html)
ES (1) ES2939775T3 (cg-RX-API-DMAC7.html)
FI (2) FI3752510T3 (cg-RX-API-DMAC7.html)
FR (1) FR25C1048I1 (cg-RX-API-DMAC7.html)
GE (2) GEP20237571B (cg-RX-API-DMAC7.html)
HR (1) HRP20230030T1 (cg-RX-API-DMAC7.html)
HU (2) HUE061046T2 (cg-RX-API-DMAC7.html)
IL (2) IL294042B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200178A1 (cg-RX-API-DMAC7.html)
LT (2) LT3752510T (cg-RX-API-DMAC7.html)
MA (1) MA51828B1 (cg-RX-API-DMAC7.html)
MD (1) MD3752510T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008268A (cg-RX-API-DMAC7.html)
NL (1) NL301356I2 (cg-RX-API-DMAC7.html)
NO (1) NO2025051I1 (cg-RX-API-DMAC7.html)
PE (1) PE20210454A1 (cg-RX-API-DMAC7.html)
PL (1) PL3752510T3 (cg-RX-API-DMAC7.html)
PT (1) PT3752510T (cg-RX-API-DMAC7.html)
RS (1) RS64018B1 (cg-RX-API-DMAC7.html)
SA (1) SA520412634B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006614VA (cg-RX-API-DMAC7.html)
SI (1) SI3752510T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300043T1 (cg-RX-API-DMAC7.html)
TW (2) TWI780304B (cg-RX-API-DMAC7.html)
UA (1) UA126304C2 (cg-RX-API-DMAC7.html)
UY (1) UY38093A (cg-RX-API-DMAC7.html)
WO (1) WO2019161078A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202004357B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64018B1 (sr) 2018-02-15 2023-03-31 Vertex Pharma Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade
MA54227B1 (fr) * 2018-11-14 2023-03-31 Vertex Pharma Méthodes de traitement de la fibrose kystique
EP3898621A1 (en) * 2018-12-21 2021-10-27 Novartis AG Macrocyclic compounds and their use in the treatment of disease
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
US11873300B2 (en) * 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
WO2021030556A1 (en) * 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TWI867024B (zh) * 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) * 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CN110551077B (zh) * 2019-09-24 2023-01-31 新乡市润宇新材料科技有限公司 一种光催化分子氧氧化制备n-叔丁基-2-苯并噻唑亚磺酰胺的方法
MX2022005810A (es) * 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113808A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Cftr-modulating arylamides
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2022194399A1 (en) * 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
WO2022076620A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en) * 2020-10-07 2023-11-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TW202233635A (zh) * 2020-10-07 2022-09-01 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
MX2023004072A (es) * 2020-10-07 2023-07-05 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
BR112023006470A2 (pt) * 2020-10-07 2023-09-26 Vertex Pharma Moduladores de regulador de condutância transmembrana de fibrose cística
US12612416B2 (en) 2020-10-07 2026-04-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en) * 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PE20231380A1 (es) * 2020-11-18 2023-09-07 Vertex Pharma Macrociclicos que contienen una anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
MX2023006770A (es) 2020-12-10 2023-08-14 Vertex Pharma Metodos de tratamiento para fibrosis quistica.
IL305881A (en) * 2021-03-16 2023-11-01 Idorsia Pharmaceuticals Ltd Macrocycles as CFTR modulators
CN119095597A (zh) 2022-02-03 2024-12-06 弗特克斯药品有限公司 治疗囊性纤维化的方法
US20250320226A1 (en) 2022-02-03 2025-10-16 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
CA3251045A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS
PE20250606A1 (es) * 2022-04-06 2025-02-26 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
AU2023273614A1 (en) 2022-05-16 2024-11-07 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20250340568A1 (en) 2022-05-16 2025-11-06 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation
IL319374A (en) 2022-09-07 2025-05-01 Sionna Therapeutics Inc Macrocyclic compounds, compositions and methods of using them
WO2024054845A1 (en) * 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
CA3267791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
CN119907667A (zh) 2022-09-15 2025-04-29 爱杜西亚药品有限公司 大环cftr调节剂与cftr校正剂和/或cftr增效剂的组合
CN115536493A (zh) * 2022-10-20 2022-12-30 海门瑞一医药科技有限公司 一种制取3,3,3-三氟甲基-2,2-二甲基丙烷醇的简单方法
AU2024397852A1 (en) * 2023-12-15 2026-07-02 Sionna Therapeutics Inc. Compounds, compositions, and methods of using thereof
WO2025166342A1 (en) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
ES3069804T3 (en) 2024-02-07 2026-06-10 Vertex Pharma Compositions for the treatment of cftr-mediated diseases
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2026128667A1 (en) * 2024-12-11 2026-06-18 Sionna Therapeutics Inc. Nbd1 modulators and methods of using the same

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2677682A (en) 1951-08-24 1954-05-04 American Cyanamid Co Sulfonamido pteridines
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
CN101675928A (zh) 2003-11-14 2010-03-24 沃泰克斯药物股份有限公司 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
WO2007053641A2 (en) 2005-11-01 2007-05-10 Mars, Incorporated A-type procyanidins and inflammation
AU2006331565A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
EP2016065B1 (en) 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセット輸送体の調節剤
ATE534383T1 (de) 2006-05-12 2011-12-15 Vertex Pharma Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
MX2009004702A (es) 2006-11-03 2009-06-19 Vertex Pharma Derivados de azaindol como moduladores del regulador de conductancia de transmembrana de fibrosis quistica.
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
RU2010114732A (ru) 2007-09-14 2011-10-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
CA2716109C (en) * 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
RS56894B1 (sr) 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
WO2010037066A2 (en) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MX2011004375A (es) * 2008-10-23 2013-03-07 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
KR20160013251A (ko) 2008-11-06 2016-02-03 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송자의 조절자
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
CN103180298A (zh) 2010-03-19 2013-06-26 沃泰克斯药物股份有限公司 N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
EP2563778B1 (en) 2010-03-25 2016-08-24 Vertex Pharmaceuticals Incorporated Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
TWI549950B (zh) 2010-04-07 2016-09-21 維泰克斯製藥公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド (r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
EP2838882A1 (en) 2012-04-20 2015-02-25 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN103571906B (zh) 2012-07-27 2018-12-11 上海泽元海洋生物技术有限公司 一种利用微藻高效生产虾青素的新方法
KR102396897B1 (ko) 2012-11-02 2022-05-13 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환의 치료를 위한 약제학적 조성물
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
HK1258472A1 (zh) 2015-09-21 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftr增效剂的施用
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
WO2017177124A1 (en) 2016-04-07 2017-10-12 Proteostasis Therapeutics, Inc. Silicone atoms containing ivacaftor analogues
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
ES2954658T3 (es) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3532461A1 (en) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
US20190248779A1 (en) 2016-10-26 2019-08-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA3041676A1 (en) 2016-10-26 2018-05-03 Daniel Parks Pyridazine derivatives, compositions and methods for modulating cftr
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
SG10202106949XA (en) 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
EA202192783A1 (ru) * 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
CN110300589B (zh) 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
CA3061476A1 (en) 2017-04-28 2018-11-01 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
CA3068609A1 (en) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
CA3069225A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3662079A4 (en) 2017-07-31 2021-04-14 Technion Research & Development Foundation Limited Methods of detecting modified and unmodified dna
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20210369749A1 (en) 2017-10-06 2021-12-02 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
WO2019113089A1 (en) 2017-12-04 2019-06-13 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
RS64018B1 (sr) 2018-02-15 2023-03-31 Vertex Pharma Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade
WO2019191620A1 (en) 2018-03-30 2019-10-03 Vertex Pharmaceuticals Incorporated Crystalline forms of modulators of cftr
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MA54227B1 (fr) 2018-11-14 2023-03-31 Vertex Pharma Méthodes de traitement de la fibrose kystique
EP3898621A1 (en) 2018-12-21 2021-10-27 Novartis AG Macrocyclic compounds and their use in the treatment of disease
JP2022519301A (ja) 2019-02-06 2022-03-22 ノバルティス アーゲー N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体及び疾患の処置におけるそれらの使用
WO2020191227A1 (en) 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
WO2020242935A1 (en) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
WO2021030556A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3158057A1 (en) 2019-11-12 2021-05-20 Genzyme Corporation 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
MX2022005810A (es) 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators

Similar Documents

Publication Publication Date Title
JP2022545359A5 (cg-RX-API-DMAC7.html)
KR102381295B1 (ko) {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도
JP2021534124A5 (cg-RX-API-DMAC7.html)
ES2385505T3 (es) N-fenilmetil-5-oxo-prolina-2-amidas sustituidas como antagonistas del receptor P2X7 y métodos de uso
JP6359563B2 (ja) 3−(5置換−4−オキソキナゾリン−3(4h)−イル)−3−ジュウテロピペリジン−2,6−ジオン誘導体
JP2008528447A5 (cg-RX-API-DMAC7.html)
JP2023531311A5 (cg-RX-API-DMAC7.html)
JP2022533398A5 (cg-RX-API-DMAC7.html)
JP2022545633A5 (cg-RX-API-DMAC7.html)
JP2019518050A5 (cg-RX-API-DMAC7.html)
JP2023520400A5 (cg-RX-API-DMAC7.html)
RU2006134020A (ru) Конденсированные производные пиразола
JP2005530722A5 (cg-RX-API-DMAC7.html)
HRP20230030T1 (hr) Makrocikli kao modulatori regulatora provodljivosti transmembrane cistične fibroze, njihovi farmaceutski pripravci, njihova uporaba u liječenju cistične fibroze, i postupak za njihovu proizvodnju
JP2006515858A5 (cg-RX-API-DMAC7.html)
RU2011140064A (ru) Ингибиторы тирозинкиназы брутона
JP2007524696A5 (cg-RX-API-DMAC7.html)
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
JPS6277386A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP2011526917A5 (cg-RX-API-DMAC7.html)
JP2023520396A5 (cg-RX-API-DMAC7.html)
JP2019527724A5 (cg-RX-API-DMAC7.html)
IE922523A1 (en) New 5-isoquinolinesulfonamides process for preparing them and pharmaceutical compositions containing them
JP2018532788A5 (cg-RX-API-DMAC7.html)
JP2020111571A5 (cg-RX-API-DMAC7.html)